Merck establishes platform to advance innovation in cancer therapies

27-Jun-2013 - Germany

Merck Serono announced its commitment to the field of cancer immunotherapy by creating a fully dedicated immuno-oncology innovation platform integrating research, early development and biomarker strategies. In addition to the company’s existing oncology platform, this new immuno-oncology platform will focus on developing therapies that leverage the immune system’s natural ability to fight tumors, and work in combination with existing and future therapies.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances